323 related articles for article (PubMed ID: 35470078)
1. Gold-seaurchin based immunomodulator enabling photothermal intervention and αCD16 transfection to boost NK cell adoptive immunotherapy.
Lin X; Li F; Gu Q; Wang X; Zheng Y; Li J; Guan J; Yao C; Liu X
Acta Biomater; 2022 Jul; 146():406-420. PubMed ID: 35470078
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy.
Fantini M; Arlen PM; Tsang KY
Front Immunol; 2023; 14():1275904. PubMed ID: 38077389
[TBL] [Abstract][Full Text] [Related]
3. High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells.
Clara JA; Levy ER; Reger R; Barisic S; Chen L; Cherkasova E; Chakraborty M; Allan DSJ; Childs R
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35135865
[TBL] [Abstract][Full Text] [Related]
4. Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment.
Portillo AL; Monteiro JK; Rojas EA; Ritchie TM; Gillgrass A; Ashkar AA
Front Immunol; 2023; 14():1286750. PubMed ID: 38022679
[TBL] [Abstract][Full Text] [Related]
5. Nanoengineered CAR-T Biohybrids for Solid Tumor Immunotherapy with Microenvironment Photothermal-Remodeling Strategy.
Chen Z; Pan H; Luo Y; Yin T; Zhang B; Liao J; Wang M; Tang X; Huang G; Deng G; Zheng M; Cai L
Small; 2021 Apr; 17(14):e2007494. PubMed ID: 33711191
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cells and cancer therapy, what we know and where we are going.
Ghaemdoust F; Keshavarz-Fathi M; Rezaei N
Immunotherapy; 2019 Oct; 11(14):1231-1251. PubMed ID: 31422725
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment.
Grote S; Ureña-Bailén G; Chan KC; Baden C; Mezger M; Handgretinger R; Schleicher S
Cells; 2021 Apr; 10(5):. PubMed ID: 33925968
[TBL] [Abstract][Full Text] [Related]
8. Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells.
Meng F; Zhang S; Xie J; Zhou Y; Wu Q; Lu B; Zhou S; Zhao X; Li Y
J Hematol Oncol; 2023 Jun; 16(1):62. PubMed ID: 37316891
[TBL] [Abstract][Full Text] [Related]
9. Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer.
Kennedy PR; Felices M; Miller JS
Stem Cell Res Ther; 2022 Apr; 13(1):165. PubMed ID: 35414042
[TBL] [Abstract][Full Text] [Related]
10. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
[TBL] [Abstract][Full Text] [Related]
11. Programmed Remodeling of the Tumor Milieu to Enhance NK Cell Immunotherapy Combined with Chemotherapy for Pancreatic Cancer.
Yang X; Li C; Yang H; Li T; Ling S; Zhang Y; Wu F; Liu X; Liu S; Fan C; Wang Q
Nano Lett; 2024 Mar; 24(11):3421-3431. PubMed ID: 38377170
[TBL] [Abstract][Full Text] [Related]
12. Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.
Bareke H; Ibáñez-Navarro A; Guerra-García P; González Pérez C; Rubio-Aparicio P; Plaza López de Sabando D; Sastre-Urgelles A; Ortiz-Cruz EJ; Pérez-Martínez A
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176035
[TBL] [Abstract][Full Text] [Related]
13. Targeting Natural Killer Cells for Tumor Immunotherapy.
Zhang C; Hu Y; Shi C
Front Immunol; 2020; 11():60. PubMed ID: 32140153
[TBL] [Abstract][Full Text] [Related]
14. Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors.
Ghaedrahmati F; Esmaeil N; Abbaspour M
Cancer Commun (Lond); 2023 Feb; 43(2):177-213. PubMed ID: 36585761
[TBL] [Abstract][Full Text] [Related]
15. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
Ben-Shmuel A; Biber G; Barda-Saad M
Front Immunol; 2020; 11():275. PubMed ID: 32153582
[TBL] [Abstract][Full Text] [Related]
16. Target tumor microenvironment by innate T cells.
Li YR; Wilson M; Yang L
Front Immunol; 2022; 13():999549. PubMed ID: 36275727
[TBL] [Abstract][Full Text] [Related]
17. Antibody-Dependent Cell-Mediated Cytotoxicity Through Natural Killer (NK) Cells: Unlocking NK Cells for Future Immunotherapy.
Chin DS; Lim CSY; Nordin F; Arifin N; Jun TG
Curr Pharm Biotechnol; 2022; 23(4):552-578. PubMed ID: 34414871
[TBL] [Abstract][Full Text] [Related]
18. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
19. Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function.
Mantesso S; Geerts D; Spanholtz J; Kučerová L
Front Immunol; 2020; 11():607131. PubMed ID: 33391277
[TBL] [Abstract][Full Text] [Related]
20. Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond.
Lin C; Horwitz ME; Rein LAM
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]